Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients. A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these,...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
13 February 2018
|
| In: |
British journal of cancer
Year: 2018, Volume: 118, Issue: 6, Pages: 785-792 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/bjc.2017.489 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2017.489 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bjc2017489 
|
| Author Notes: | Markus Hecht, Friedegund Meier, Lisa Zimmer, Bülent Polat, Carmen Loquai, Carsten Weishaupt, Andrea Forschner, Ralf Gutzmer, Jochen S. Utikal, Simone M. Goldinger, Michael Geier, Jessica C. Hassel, Panagiotis Balermpas, Felix Kiecker, Ricarda Rauschenberg, Ursula Dietrich, Patrick Clemens, Carola Berking, Gerhard Grabenbauer, Dirk Schadendorf, Stephan Grabbe, Gerold Schuler, Rainer Fietkau, Luitpold V. Distel & Lucie Heinzerling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1696741920 | ||
| 003 | DE-627 | ||
| 005 | 20220818055542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200428s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/bjc.2017.489 |2 doi | |
| 035 | |a (DE-627)1696741920 | ||
| 035 | |a (DE-599)KXP1696741920 | ||
| 035 | |a (OCoLC)1341317275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hecht, Markus |d 1985- |e VerfasserIn |0 (DE-588)1018554793 |0 (DE-627)690632096 |0 (DE-576)35602458X |4 aut | |
| 245 | 1 | 0 | |a Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients |c Markus Hecht, Friedegund Meier, Lisa Zimmer, Bülent Polat, Carmen Loquai, Carsten Weishaupt, Andrea Forschner, Ralf Gutzmer, Jochen S. Utikal, Simone M. Goldinger, Michael Geier, Jessica C. Hassel, Panagiotis Balermpas, Felix Kiecker, Ricarda Rauschenberg, Ursula Dietrich, Patrick Clemens, Carola Berking, Gerhard Grabenbauer, Dirk Schadendorf, Stephan Grabbe, Gerold Schuler, Rainer Fietkau, Luitpold V. Distel & Lucie Heinzerling |
| 264 | 1 | |c 13 February 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.04.2020 | ||
| 520 | |a Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients. A total of 155 patients with BRAF-mutated melanoma from 17 European skin cancer centres were retrospectively analysed. Out of these, 87 patients received concomitant radiotherapy and BRAFi (59 vemurafenib, 28 dabrafenib), while in 68 patients BRAFi therapy was interrupted during radiation (51 vemurafenib, 17 dabrafenib). Overall survival was calculated from the first radiation (OSRT) and from start of BRAFi therapy (OSBRAFi). The median duration of BRAFi treatment interruption prior to radiotherapy was 4 days and lasted for 17 days. Median OSRT and OSBRAFi in the entire cohort were 9.8 and 12.6 months in the interrupted group and 7.3 and 11.5 months in the concomitant group (P=0.075/P=0.217), respectively. Interrupted vemurafenib treatment with a median OSRT and OSBRAFi of 10.1 and 13.1 months, respectively, was superior to concomitant vemurafenib treatment with a median OSRT and OSBRAFi of 6.6 and 10.9 months (P=0.004/P=0.067). Interrupted dabrafenib treatment with a median OSRT and OSBRAFi of 7.7 and 9.8 months, respectively, did not differ from concomitant dabrafenib treatment with a median OSRT and OSBRAFi of 9.9 and 11.6 months (P=0.132/P=0.404). Median local control of the irradiated area did not differ in the interrupted and concomitant BRAFi treatment groups (P=0.619). Skin toxicity of grade ≥2 (CTCAE) was significantly increased in patients with concomitant vemurafenib compared to the group with treatment interruption (P=0.002). Interruption of vemurafenib treatment during radiation was associated with better survival and less toxicity compared to concomitant treatment. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated. The results of this analysis indicate that treatment with the BRAFi vemurafenib should be interrupted during radiotherapy. Prospective studies are desperately needed. | ||
| 700 | 1 | |a Meier, Friedegund |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zimmer, Lisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Polat, Bülent |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loquai, Carmen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weishaupt, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Forschner, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gutzmer, Ralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Goldinger, Simone M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geier, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Balermpas, Panagiotis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kiecker, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rauschenberg, Ricarda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dietrich, Ursula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clemens, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berking, Carola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grabenbauer, Gerhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Grabbe, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schuler, Gerold |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fietkau, Rainer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Distel, Luitpold V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzerling, Lucie |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d Edinburgh : Nature Publ. Group, 1947 |g 118(2018), 6, Seite 785-792 |h Online-Ressource |w (DE-627)320420094 |w (DE-600)2002452-6 |w (DE-576)103746854 |x 1532-1827 |7 nnas |a Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients |
| 773 | 1 | 8 | |g volume:118 |g year:2018 |g number:6 |g pages:785-792 |g extent:8 |a Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients |
| 856 | 4 | 0 | |u https://doi.org/10.1038/bjc.2017.489 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/bjc2017489 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200428 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 20 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 12 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 9 | ||
| 999 | |a KXP-PPN1696741920 |e 3639811275 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Markus Hecht, Friedegund Meier, Lisa Zimmer, Bülent Polat, Carmen Loquai, Carsten Weishaupt, Andrea Forschner, Ralf Gutzmer, Jochen S. Utikal, Simone M. Goldinger, Michael Geier, Jessica C. Hassel, Panagiotis Balermpas, Felix Kiecker, Ricarda Rauschenberg, Ursula Dietrich, Patrick Clemens, Carola Berking, Gerhard Grabenbauer, Dirk Schadendorf, Stephan Grabbe, Gerold Schuler, Rainer Fietkau, Luitpold V. Distel & Lucie Heinzerling"]},"id":{"eki":["1696741920"],"doi":["10.1038/bjc.2017.489"]},"physDesc":[{"extent":"8 S."}],"recId":"1696741920","relHost":[{"recId":"320420094","physDesc":[{"extent":"Online-Ressource"}],"disp":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsBritish journal of cancer","origin":[{"dateIssuedKey":"1947","publisherPlace":"Edinburgh ; Edinburgh","dateIssuedDisp":"1947-","publisher":"Nature Publ. Group ; Churchill Livingstone"}],"title":[{"title":"British journal of cancer","title_sort":"British journal of cancer","subtitle":"BJC"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 27.10.25"],"titleAlt":[{"title":"BJC"}],"pubHistory":["Volume 1, issue 1 (1 March 1947)-"],"id":{"eki":["320420094"],"issn":["1532-1827"],"zdb":["2002452-6"]},"part":{"volume":"118","year":"2018","issue":"6","extent":"8","text":"118(2018), 6, Seite 785-792","pages":"785-792"}}],"person":[{"display":"Hecht, Markus","given":"Markus","role":"aut","family":"Hecht"},{"role":"aut","given":"Friedegund","family":"Meier","display":"Meier, Friedegund"},{"role":"aut","given":"Lisa","family":"Zimmer","display":"Zimmer, Lisa"},{"given":"Bülent","role":"aut","family":"Polat","display":"Polat, Bülent"},{"family":"Loquai","given":"Carmen","role":"aut","display":"Loquai, Carmen"},{"display":"Weishaupt, Carsten","role":"aut","given":"Carsten","family":"Weishaupt"},{"given":"Andrea","role":"aut","family":"Forschner","display":"Forschner, Andrea"},{"display":"Gutzmer, Ralf","role":"aut","given":"Ralf","family":"Gutzmer"},{"family":"Utikal","given":"Jochen","role":"aut","display":"Utikal, Jochen"},{"display":"Goldinger, Simone M.","role":"aut","given":"Simone M.","family":"Goldinger"},{"role":"aut","given":"Michael","family":"Geier","display":"Geier, Michael"},{"display":"Hassel, Jessica C.","family":"Hassel","given":"Jessica C.","role":"aut"},{"display":"Balermpas, Panagiotis","family":"Balermpas","given":"Panagiotis","role":"aut"},{"display":"Kiecker, Felix","family":"Kiecker","role":"aut","given":"Felix"},{"family":"Rauschenberg","role":"aut","given":"Ricarda","display":"Rauschenberg, Ricarda"},{"display":"Dietrich, Ursula","family":"Dietrich","given":"Ursula","role":"aut"},{"display":"Clemens, Patrick","family":"Clemens","role":"aut","given":"Patrick"},{"display":"Berking, Carola","given":"Carola","role":"aut","family":"Berking"},{"display":"Grabenbauer, Gerhard","role":"aut","given":"Gerhard","family":"Grabenbauer"},{"given":"Dirk","role":"aut","family":"Schadendorf","display":"Schadendorf, Dirk"},{"display":"Grabbe, Stephan","given":"Stephan","role":"aut","family":"Grabbe"},{"given":"Gerold","role":"aut","family":"Schuler","display":"Schuler, Gerold"},{"display":"Fietkau, Rainer","family":"Fietkau","given":"Rainer","role":"aut"},{"display":"Distel, Luitpold V.","family":"Distel","role":"aut","given":"Luitpold V."},{"display":"Heinzerling, Lucie","role":"aut","given":"Lucie","family":"Heinzerling"}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"13 February 2018"}],"note":["Gesehen am 28.04.2020"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients","title_sort":"Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients"}]} | ||
| SRT | |a HECHTMARKUCLINICALOU1320 | ||